Dal-Ré Rafael, Bobes Julio, Cuijpers Pim
Clinical Research, BUC (Biosciences UAM+CSIC) Program, International Campus of Excellence, Universidad Autónoma de Madrid, Ciudad Universitaria de Cantoblanco, c/Einstein 3, 28049, Madrid, Spain.
Department of Psychiatry, School of Medicine, University of Oviedo, C/ San Francisco, 1, 33003, Oviedo, Asturias, Spain.
Trials. 2017 Mar 28;18(1):143. doi: 10.1186/s13063-017-1899-2.
Clinical trial results' reliability is impacted by reporting bias. This is primarily manifested as publication bias and outcome reporting bias.
MENTAL HEALTH TRIALS' SPECIFIC FEATURES: Mental health trials are prone to two methodological deficiencies: (1) using small numbers of participants that facilitates false positive findings and exaggerated size effects, and (2) the obligatory use of psychometric scales that require subjective assessments. These two deficiencies contribute to the publication of unreliable results. Considerable reporting bias has been found in safety and efficacy findings in psychotherapy and pharmacotherapy trials. Reporting bias can be carried forward to meta-analyses, a key source for clinical practice guidelines. The final result is the frequent overestimation of treatment effects that could impact patients and clinician-informed decisions.
Prospective registration of trials and publication of results are the two major methods to reduce reporting bias. Prospective trial registration will allow checking whether they are published (so it will help to prevent publication bias) and, if published, whether those outcomes and analyses that were deemed as appropriate before trial commencement are actually published (hence helping to find out selective reporting of outcomes). Unfortunately, the rate of registered trials in mental health interventions is low and, frequently, of poor quality.
Clinicians should be prudent when interpreting the results of published trials and some meta-analyses - such as those conducted by scientists working for the sponsor company or those that only include published trials. Prescribers, however, should be confident when prescribing drugs following the summary of product characteristics, since regulatory agencies have access to all clinical trial results.
临床试验结果的可靠性受到报告偏倚的影响。这主要表现为发表偏倚和结果报告偏倚。
心理健康试验容易出现两个方法学缺陷:(1)使用的参与者数量较少,这便于得出假阳性结果并夸大效应量,(2)必须使用需要主观评估的心理测量量表。这两个缺陷导致不可靠结果的发表。在心理治疗和药物治疗试验的安全性和有效性结果中发现了相当大的报告偏倚。报告偏倚可能会延续到荟萃分析中,而荟萃分析是临床实践指南的一个关键来源。最终结果是经常高估治疗效果,这可能会影响患者和临床医生的决策。
试验的前瞻性注册和结果的发表是减少报告偏倚的两种主要方法。前瞻性试验注册将允许检查试验是否发表(因此有助于防止发表偏倚),以及如果发表,在试验开始前被认为合适的那些结果和分析是否实际发表(从而有助于发现结果的选择性报告)。不幸的是,心理健康干预试验的注册率很低,而且质量往往很差。
临床医生在解释已发表试验和一些荟萃分析的结果时应谨慎,比如由申办公司的科学家进行的那些分析或那些只纳入已发表试验的分析。然而,开药者在根据产品特性摘要开药时应充满信心,因为监管机构可以获取所有临床试验结果。